- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 31.03. | Virax Biolabs' Investigational Diagnostic Tests Has An Attractive Market Opportunity', Analyst Initiates With Buy Rating | 5 | Benzinga.com | ||
| 18.03. | Virax Biolabs Enrolls First Patients in Clinical Study Assessing T cell Dysfunction in Post-acute Infection Syndromes | 79 | PR Newswire | LONDON, March 18, 2025 /PRNewswire/ -- Virax Biolabs Group Limited (NASDAQ: VRAX) ("Virax" or the "Company"), an innovative biotechnology company focused on... ► Artikel lesen | |
| 18.03. | Virax Biolabs begins UK clinical study on T cell dysfunction | 1 | Investing.com | ||
| VIRAX BIOLABS GROUP Aktie jetzt für 0€ handeln | |||||
| 13.03. | Virax Biolabs Presents Findings On T-Cell Dysfunction In Post-Acute Infection Syndromes | 1 | RTTNews | ||
| 13.03. | Virax Biolabs Group Ltd - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 13.03. | Virax Biolabs shares T-Cell dysfunction findings | 2 | Investing.com | ||
| 05.03. | Virax Biolabs Group Ltd - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 25.02. | EXCLUSIVE: Virax Biolabs Says Its Tech Fits RFK Jr.'s HHS Goals On Vaccine Transparency | 4 | Benzinga.com | ||
| 25.02. | Virax Biolabs Group Ltd - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 30.01. | Virax Biolabs Group Ltd - S-8, Securities to be offered to employees in employee benefit plans | - | SEC Filings | ||
| 23.01. | Cosmos Health Inc.: Cosmos Health Signs Expanded Exclusive Distribution Agreement with Virax Biolabs for Avian Influenza Virus PCR Kits in Saudi Arabia, the UAE, Qatar, and Kuwait | 464 | ACCESS Newswire | CHICAGO, IL / ACCESS Newswire / January 23, 2025 / Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative... ► Artikel lesen | |
| 13.01. | Cosmos Health announces distribution agreement with Virax Biolabs | 3 | Seeking Alpha | ||
| 13.01. | Cosmos Health Inc.: Cosmos Health Secures Exclusive Distribution Agreement with Virax Biolabs for Avian Influenza Virus PCR Kits in Greece and Cyprus, with Additional Rights in Select European and GCC Countries | 335 | ACCESS Newswire | CHICAGO, IL / ACCESSWIRE / January 13, 2025 / Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative... ► Artikel lesen | |
| 17.12.24 | Virax Biolabs Group Ltd - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 10.12.24 | Virax Biolabs Group Ltd - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 06.12.24 | Virax Biolabs: Interview With COO Nigel McCracken About The Diagnostics And Detection Company | 1 | pulse2.com | ||
| 20.11.24 | Virax Biolabs Group Ltd - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 31.10.24 | Virax Biolabs announces 2024 annual meeting | 2 | Investing.com | ||
| 31.10.24 | Virax Biolabs kündigt Jahreshauptversammlung 2024 an | - | Investing.com Deutsch | ||
| 31.10.24 | Virax Biolabs Group Ltd - 6-K, Report of foreign issuer | - | SEC Filings |
Seite:
1 2 Weiter >>
25 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 102,10 | -0,10 % | BioNTech-Aktie: Ein schnelles Ende! | News von Trading-Treff.de BioNTech schafft es derzeit einfach nicht, die negativen Stimmungen am Markt zu besiegen. Die Aktie verlor am Donnerstag rund 1,6 %. Damit ist der Wert wieder auf dem Weg in... ► Artikel lesen | |
| EVOTEC | 7,382 | +0,52 % | Aktien KW 16 Erholung. Aber: Death Cross als Crash-Menetekel? Oder gibt's Hoffnung? News. Rheinmetall. Kontron. Evotec. Nvidia. Hamborner REIT. MHP Hotels. Forvia Hella. Hensoldt. Circus. Berentzen. Fortec. Carl Zeiss MediTec. Drägerwerk. Agnicio Mining | Aktien Wochenrückblick - die Märkte scheinen sich langsam an die Zitterphase zu gewöhnen. Aktuelle Kurserholung dauerhaft? Oder was kommt noch: Zollankündigung, Handelskrieg mit China, 90 Tage Moratorium... ► Artikel lesen | |
| BAVARIAN NORDIC | 20,360 | -0,97 % | Bavarian Nordic Aktie: Zweifel unbegründet? | Trotz heutigem Plus verzeichnet die Bavarian Nordic Aktie erhebliche Verluste seit Jahresbeginn. Technische Indikatoren deuten auf weitere Schwäche hin. Blutbad im LangfristchartAnzeigeSollten Anleger... ► Artikel lesen | |
| ASEP MEDICAL | 0,400 | 0,00 % | XFRA NEW INSTRUMENTS AVAILABLE ON 17.04.2025 | The following instruments on XETRA do have their first trading 17.04.2025 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag 17.04.2025
Aktien
1 AU0000082422 Harvest Technology Group... ► Artikel lesen | |
| EMERGENT BIOSOLUTIONS | 4,715 | +8,24 % | Emergent BioSolutions Aktie: Wirtschaftliche Betrachtung | Biotech-Unternehmen kündigt Rückkaufprogramm an, während Analysten einstimmig Kaufempfehlungen aussprechen. Die Aktie zeigt starke Schwankungen vor wichtigen Quartalsdaten. Aktienrückkauf als VertrauenssignalAnzeigeSollten... ► Artikel lesen | |
| GINKGO BIOWORKS | 7,000 | +1,45 % | Ginkgo Bioworks Reports Fourth Quarter and Full Year 2024 Financial Results | Ginkgo provides update on its restructuring process including significant improvement in cash flow in the fourth quarter, completion of site consolidation and an... ► Artikel lesen | |
| GENPREX | 1,820 | -100,00 % | Genprex presents promising gene therapy data for lung cancer | ||
| PALISADE BIO | 0,730 | 0,00 % | Palisade Bio, Inc.: Palisade Bio Completes Dosing in Phase 1a Portion of Ongoing Phase 1a/b Study of PALI-2108 | Sustained positive preliminary data from all completed single ascending dose (SAD) cohorts, multiple ascending dose (MAD) cohorts, and food effects crossover, further supporting the safety and tolerability... ► Artikel lesen | |
| GRITSTONE BIO | 0,016 | -100,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 19.12.2024 | The following instruments on Boerse Frankfurt do have their last trading day on 19.12.2024Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 19.12.2024ISIN NameUS23636BAV18 DANSKE... ► Artikel lesen | |
| SIGA TECHNOLOGIES | 6,440 | -0,46 % | SIGA Technologies - Dividends bring cheer amid market uncertainty | SIGA Technologies has declared a special dividend of $0.6 per share, marking a fourth straight year of dividend declarations. The outlay is at a similar level to the one paid in March 2024 ($43m based... ► Artikel lesen | |
| GEOVAX LABS | 2,685 | -100,00 % | Nitches, inc: Nitches Inc. Updates Shareholders on Amazon Integration, GovX Integration, and 2025 Growth Strategy for InTheZone Labs | LAS VEGAS, NV / ACCESSWIRE / December 18, 2024 / Nitches Inc. (OTC PINK:NICH) is pleased to share key updates regarding the recent strides made with its InTheZone Labs brand, highlighting successful... ► Artikel lesen | |
| SYROS PHARMACEUTICALS | 0,108 | -100,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 25.03.2025 | The following instruments on Boerse Frankfurt do have their last trading day on 25.03.2025.Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 25.03.2025.ISIN NameCA05553A1075 THE... ► Artikel lesen | |
| ANNOVIS BIO | 1,440 | +1,55 % | Annovis Bio Inc.: Annovis Bio, Inc. Receives Continued Listing Standard Notice From the NYSE | MALVERN, Pa., March 27, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative... ► Artikel lesen | |
| SAGIMET BIOSCIENCES | 2,500 | -9,42 % | Sagimet Biosciences Inc.: Sagimet Biosciences Announces Upcoming Presentations at EASL Congress 2025 | ||
| HUMACYTE | 1,450 | -2,03 % | Humacyte, Inc: Humacyte Announces Fourth Quarter and Year End 2024 Financial Results and Provides Business Update | - Received U.S. Food and Drug Administration (FDA) approval of Symvess (acellular tissue engineered vessel-tyod) for the treatment of extremity vascular trauma - - Commenced market launch and first... ► Artikel lesen |
VIRAX BIOLABS GROUP LIMITED gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 1,070 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu VIRAX BIOLABS GROUP LIMITED finden Sie auf Wallstreet Online.
